Phase 1 study of an anti-CD27 agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors

Authors
Category Primary study
JournalJournal for ImmunoTherapy of Cancer
Year 2020
This article has no abstract
Epistemonikos ID: d49c71d6c3eff149994385ce50dc5053af403f30
First added on: Feb 11, 2025